Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34 + cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation

2021 ◽  
Author(s):  
Sang‐Mi Kim ◽  
Hyun‐Young Kim ◽  
Seok Jin Kim ◽  
Jun Ho Jang ◽  
Kihyun Kim ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Peripheral Blood Stem Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor ◽  
Cell Counts ◽  
Flow Cytometric ◽  
Blood Stem Cell Transplantation

Hematopoietic Progenitor Cell Counts Is a Useful Indicator To Determine Appropriate Time For Peripheral Blood Stem Cell Collection

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2037-2037
Author(s):  
Sun-Young Kong ◽  
Hyoeun Shim ◽  
Se-Na Lee ◽  
Jung-Hee Kong ◽  
Hyeon-Seok Eom ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Peripheral Blood Stem Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor ◽  
Non Hodgkin Lymphoma ◽  
Cell Counts ◽  
Cd34 Cells

Abstract Background The optimal peripheral blood stem cell (PBSC) collection is a key step for successful outcome in hematopoietic stem cell transplantation (HSCT). Many indicators including preharvest white blood cell (WBC), mononuclear cell (MNC), and CD34 positive cell counts have been used for deciding the adequate time for collection of PBSCs, but each indicator has limitations. Here we investigated hematopoietic progenitor cell (HPC) count as an indicator for PBSC collection. Methods: Data from 851 autologous PBSC collections from 233 patients at the National Cancer Center, Korea, were analyzed. The correlations between harvested CD34 cell counts with preharvest WBC, MNC, CD34 cell counts, and HPC were analyzed, as were correlations by disease and mobilizing agent. Also how the outcome for engraftment can be predicted based on HPC count was studied. Results: The median age of patients was 41 years (range 0.1-72 years). The most frequent diseases were multiple myeloma (n=64) and non-Hodgkin lymphoma (n=56). The correlation coefficient between collected CD34 cells and preharvest CD34 count was (r=0.669, p<0.001), followed by preharvest HPC count (r=0.419, p<0.001), preharvest MNC (r=0.190, p<0.001) and preharvest WBC (r=0.014, p=0.679). The most adequate cut-off value for obtaining >1x106 CD34+ cells/kg at first time of PBSC was 24.0 HPCs/μL with sensitivity and specificity of 67.7% and 74.3% respectively. The cutoff as 28.0 HPCs/μL was adequate for obtaining 2.0 x106 CD34+ cells/kg with sensitivity and specificity of 73.7% and 72.2% respectively. HPC was well correlated with CD34 in PBSC of patients with multiple myeloma (r=0.326, p=0.009), non-Hodgkin lymphoma (r=0.353, p=0.008), especially diffuse large B-cell lymphoma (r=0.810, p<0.001) and acute leukemia (r=0.998, p<0.001). HPC was a better indicator for non-cyclophosphamide (r=0.337, p<0.001) than cyclophosphamide-based chemomobilization (r=0.572, p=0.052). Infused number of HPCs did not affect the times to engraftment of platelets (p=0.896) and neutrophils (p=0.953), though CD34 count of infusion had positive effect on platelet engraftment (p=0.017). Conclusion: HPC count represented good correlation with CD34+ and high area under the curve. Considering advantages of ease for use and cost-effectiveness than those of CD34 count, HPC is a good surrogate marker to determine appropriate timing for PBSC. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Clinical Usefulness of the Hematopoietic Progenitor Cell Counts in Predicting the Optimal Timing of Peripheral Blood Stem Cell Harvest

2003 ◽  
Vol 18 (1) ◽  
pp. 27 ◽  
Author(s):  
Jae-Lyun Lee ◽  
Sung-Bae Kim ◽  
Gyeong-Won Lee ◽  
Min-Hee Ryu ◽  
Eun-Kyeong Kim ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Peripheral Blood Stem Cell ◽  
Clinical Usefulness ◽  
Hematopoietic Progenitor Cell ◽  
Optimal Timing ◽  
Hematopoietic Progenitor ◽  
Cell Counts ◽  
Cell Harvest

scholarly journals Evaluation of new automated hematopoietic progenitor cell analysis in the clinical management of peripheral blood stem cell collections

Transfusion ◽  
2015 ◽  
Vol 55 (8) ◽  
pp. 2001-2009 ◽  
Author(s):  
Ellinor I. Peerschke ◽  
Christine Moung ◽  
Melissa S. Pessin ◽  
Peter Maslak
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Clinical Management ◽  
Progenitor Cell ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Hematopoietic Progenitor Cell ◽  
Cell Analysis ◽  
Hematopoietic Progenitor

Use of hematopoietic progenitor cell count on the Sysmex XE-2100 for peripheral blood stem cell harvest monitoring

2007 ◽  
Vol 48 (1) ◽  
pp. 89-96 ◽  
Author(s):  
Rémi Letestu ◽  
Christophe Marzac ◽  
Françoise Audat ◽  
Ramdane Belhocine ◽  
Sylvie Tondeur ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Count ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor ◽  
Cell Harvest

scholarly journals HEMATOPOIETIC PROGENITOR CELL COUNT AS AN INDICATOR OF OPTIMAL PERIPHERAL BLOOD STEM CELL HARVEST TIMING BOTH IN PATIENTS AND HEALTHY DONORS

2018 ◽  
Vol 64 (1) ◽  
pp. 50-58 ◽  
Author(s):  
Shinya Mizumura ◽  
Shinji Yoshii ◽  
Maiko Mizumura ◽  
Mariko Hiromatsu ◽  
Noriko Seki ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Count ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Peripheral Blood Stem Cell ◽  
Hematopoietic Progenitor Cell ◽  
Hematopoietic Progenitor ◽  
Healthy Donors ◽  
Harvest Timing ◽  
Cell Harvest

Pegfilgrastrim Compared with Filgrastim after Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5287-5287
Author(s):  
Gaetan Vanstraelen ◽  
Pascale Frère ◽  
Marie-Christine Ngirabacu ◽  
Evelyne Willems ◽  
Georges Fillet ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Outcome ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Cell Counts ◽  
Cd34 Cells ◽  
Blood Stem Cell Transplantation

Abstract In order to assess the effect of Pegfilgrastim on the duration of neutropenia and clinical outcome of patients after autologous peripheral blood stem cell transplantation (PBSCT), we compared 20 consecutive patients with lymphoma or multiple myeloma receiving a single 6 mg dose of Pegfilgrastim on day 1 posttransplant to a historical control group of 60 patients receiving daily Filgrastim 5 μg/kg starting on day 1 posttransplant. There were 54 M and 26 F, 30 patients with lymphoma and 50 with myeloma, 26 in CR and 54 not in CR. Mean age was 55±10 yrs and 25 had already received a previous autologous transplant. The two groups were matched for disease and disease status, transplant number, age and sex. Cell dose infused tended to be higher in the Pegfilgrastim group (7.16±3.82 vs 10.03±6.25 x106 CD34+ cells/kg, p=0.0575). There were no differences (p&gt;0.05) in time to 0.5 (8 vs 9 days) or 1 (9 vs 9 days) x109/L neutrophils; to 1 % reticulocytes (13 vs 15 days) or 9 (12 vs 14 days) or 10 (30 vs 25 days) g/dL Hb; to 20 (9 vs 9 days) or 100 (20 vs 31 days) x 109/L platelets. The number of days with fever (2.7±2.3 vs 2.3±2.4 days), incidence of infections (all infections; bacteremia; bacterial, fungal or viral infections; FUO), duration of antibiotic therapy (8.7±5.9 vs 8.4±5.9 days), RBC (1.1±1.6 vs 0.9±1.6) and platelet (1.0±1.7 vs 1.2±1.8) transfusions, and time to hospital discharge (14.5±5.3 vs 15.4±5.8 days) were similar in the Pegfilgrastim compared to the Filgrastim group. However, after initial hematopoietic recovery, several differences between the groups became apparent, with the group always showing higher counts compared to the Filgrastim group (p values &lt;0.05 to &lt;0.001). Neutrophils remained significantly higher in the Pegfilgrastim group between days 14–30, lymphocytes between days 56–90, monocytes between days 21–24, reticulocytes between days 17–42 and platelets between days 35–90, respectively. These differences had no impact on clinical outcome after day 30 due to the low incidence of infectious events after engraftment. We conclude that Pegfilgrastim administrated on day 1 posttransplant facilitates early hematopoietic reconstitution comparable to daily Filgrastim. However, despite a trend towards fewer CD34+ cells transplanted, the Pegfilgrastim group enjoyed higher trilineage cell counts for some time after initial engraftment. This should be further tested in prospective randomized trials.

Monitoring the Timing of Peripheral Blood Stem Cell Apheresis: Application of the Hematopoietic Progenitor Cell Analysis

2001 ◽  
Vol 28 (5) ◽  
pp. 271-276
Author(s):  
K. Gutensohn ◽  
M.M. Magens ◽  
N. Kroeger ◽  
W. Krueger ◽  
M.A. Brockmann ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Hematopoietic Progenitor Cell ◽  
Cell Analysis ◽  
Hematopoietic Progenitor
Sign in / Sign up

Export Citation Format

Share Document